ELOVL6-IN-1 is a potent, selective, and orally active inhibitor of ELOVL6, exhibiting dose-dependent inhibition of mouse ELOVL6 with an IC50 of 0.350 μM and acting as a noncompetitive inhibitor with respect to malonyl-CoA (Ki=994 nM) and palmitoyl-CoA [1].

ELOVL6-IN-1 possesses adequate lipophilicity, enabling it to potentially penetrate intracellular spaces via passive diffusion [1].

ELOVL6-IN-1, administered orally at a dosage of 10 mg/kg for a duration of 0 to 2 hours, demonstrated significant exposure in both plasma and liver [1]. At dosages of 10 and 30 mg/kg, also administered orally and within the same two-hour time frame, it reduced the elongation index of hepatic lipids [1]. Moreover, when given at a higher dose of 100 mg/kg over a two-day period, ELOVL6-IN-1 decreased the total fatty acid elongation index in the liver [1].